Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 103 | 2024 | 20988 | 3.920 |
Why?
|
Mastectomy, Segmental | 31 | 2023 | 955 | 3.360 |
Why?
|
Inflammatory Breast Neoplasms | 14 | 2024 | 147 | 2.770 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 11 | 2024 | 926 | 2.650 |
Why?
|
Radiotherapy, Adjuvant | 27 | 2024 | 1784 | 2.620 |
Why?
|
Neoplasm Recurrence, Local | 38 | 2024 | 9277 | 2.290 |
Why?
|
Mastectomy | 27 | 2024 | 1817 | 2.100 |
Why?
|
Carcinoma, Ductal, Breast | 12 | 2020 | 1084 | 1.570 |
Why?
|
Wine | 7 | 2019 | 166 | 1.500 |
Why?
|
Saccharomyces | 5 | 2015 | 63 | 1.440 |
Why?
|
Neoadjuvant Therapy | 15 | 2024 | 2827 | 0.920 |
Why?
|
Receptor, erbB-2 | 18 | 2024 | 2553 | 0.910 |
Why?
|
Sentinel Lymph Node Biopsy | 14 | 2023 | 732 | 0.900 |
Why?
|
Lymphatic Metastasis | 19 | 2023 | 2913 | 0.860 |
Why?
|
Radiation Oncology | 6 | 2023 | 563 | 0.840 |
Why?
|
Lymph Node Excision | 12 | 2023 | 1269 | 0.830 |
Why?
|
Radiation Injuries | 4 | 2021 | 1189 | 0.830 |
Why?
|
Paclitaxel | 7 | 2024 | 1730 | 0.820 |
Why?
|
Thoracic Wall | 3 | 2018 | 202 | 0.660 |
Why?
|
Lymph Nodes | 11 | 2021 | 3461 | 0.660 |
Why?
|
Chemotherapy, Adjuvant | 18 | 2023 | 3514 | 0.630 |
Why?
|
Dermatomyositis | 1 | 2021 | 258 | 0.600 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2018 | 123 | 0.570 |
Why?
|
Lymphedema | 2 | 2023 | 523 | 0.560 |
Why?
|
Axilla | 13 | 2023 | 624 | 0.540 |
Why?
|
Chimera | 2 | 2015 | 453 | 0.540 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2020 | 801 | 0.530 |
Why?
|
Carcinoma in Situ | 2 | 2020 | 791 | 0.530 |
Why?
|
Heart | 2 | 2022 | 4403 | 0.530 |
Why?
|
Benchmarking | 1 | 2022 | 1045 | 0.520 |
Why?
|
Combined Modality Therapy | 18 | 2021 | 8516 | 0.510 |
Why?
|
Fermentation | 3 | 2019 | 142 | 0.510 |
Why?
|
Mediastinal Neoplasms | 1 | 2018 | 401 | 0.500 |
Why?
|
Food Microbiology | 1 | 2015 | 74 | 0.500 |
Why?
|
Neoplasm Staging | 21 | 2023 | 11116 | 0.490 |
Why?
|
Female | 113 | 2024 | 392148 | 0.480 |
Why?
|
Hybridization, Genetic | 2 | 2013 | 102 | 0.480 |
Why?
|
Cisplatin | 1 | 2021 | 1650 | 0.480 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 11736 | 0.460 |
Why?
|
Brachytherapy | 4 | 2023 | 1223 | 0.460 |
Why?
|
Carcinoma | 3 | 2017 | 2327 | 0.450 |
Why?
|
Breast | 4 | 2023 | 1963 | 0.440 |
Why?
|
Lymphatic Irradiation | 3 | 2014 | 115 | 0.440 |
Why?
|
Carcinoma, Lobular | 5 | 2020 | 480 | 0.430 |
Why?
|
Neoplasm, Residual | 7 | 2022 | 1008 | 0.430 |
Why?
|
Premenopause | 2 | 2016 | 1038 | 0.410 |
Why?
|
Fluorouracil | 3 | 2014 | 1642 | 0.410 |
Why?
|
Mammography | 8 | 2013 | 2430 | 0.380 |
Why?
|
Receptors, Estrogen | 15 | 2022 | 2208 | 0.370 |
Why?
|
Radiotherapy Dosage | 9 | 2021 | 2897 | 0.370 |
Why?
|
Humans | 122 | 2024 | 760617 | 0.370 |
Why?
|
Cyclophosphamide | 5 | 2017 | 2218 | 0.370 |
Why?
|
Saccharomyces cerevisiae | 5 | 2019 | 2674 | 0.350 |
Why?
|
Middle Aged | 63 | 2024 | 220584 | 0.350 |
Why?
|
Wound Healing | 1 | 2021 | 2802 | 0.340 |
Why?
|
Research | 1 | 2018 | 1977 | 0.330 |
Why?
|
Receptors, Progesterone | 10 | 2020 | 1129 | 0.330 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2015 | 1655 | 0.310 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2020 | 2008 | 0.310 |
Why?
|
Methotrexate | 2 | 2005 | 1716 | 0.290 |
Why?
|
Aged, 80 and over | 26 | 2021 | 58894 | 0.290 |
Why?
|
Mastectomy, Modified Radical | 3 | 2017 | 62 | 0.260 |
Why?
|
Aged | 43 | 2024 | 169042 | 0.250 |
Why?
|
Neoplasms, Second Primary | 3 | 2024 | 1051 | 0.250 |
Why?
|
Adult | 51 | 2024 | 220969 | 0.240 |
Why?
|
Mammaplasty | 6 | 2024 | 1232 | 0.240 |
Why?
|
Follow-Up Studies | 20 | 2024 | 39063 | 0.240 |
Why?
|
Pain Measurement | 1 | 2014 | 3546 | 0.230 |
Why?
|
Salvage Therapy | 4 | 2015 | 1263 | 0.220 |
Why?
|
Radiotherapy | 4 | 2018 | 1497 | 0.210 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2005 | 349 | 0.210 |
Why?
|
Retrospective Studies | 27 | 2022 | 80566 | 0.210 |
Why?
|
Taste | 2 | 2015 | 189 | 0.200 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4058 | 0.200 |
Why?
|
Tomography, Emission-Computed | 2 | 2004 | 1122 | 0.190 |
Why?
|
Disease-Free Survival | 5 | 2016 | 6807 | 0.190 |
Why?
|
Risk | 6 | 2023 | 9604 | 0.190 |
Why?
|
Doxorubicin | 3 | 2014 | 2224 | 0.180 |
Why?
|
Treatment Outcome | 18 | 2024 | 64568 | 0.180 |
Why?
|
Tamoxifen | 3 | 2013 | 965 | 0.180 |
Why?
|
Radiotherapy, Conformal | 1 | 2023 | 548 | 0.170 |
Why?
|
Ataxia Telangiectasia | 1 | 2021 | 107 | 0.170 |
Why?
|
Brain Neoplasms | 4 | 2017 | 9026 | 0.170 |
Why?
|
Nitriles | 2 | 2024 | 971 | 0.170 |
Why?
|
Body Mass Index | 2 | 2020 | 12943 | 0.170 |
Why?
|
Taxoids | 2 | 2017 | 667 | 0.170 |
Why?
|
Cone-Beam Computed Tomography | 4 | 2012 | 474 | 0.170 |
Why?
|
Thorax | 1 | 2022 | 555 | 0.160 |
Why?
|
Pubic Bone | 1 | 1999 | 31 | 0.160 |
Why?
|
Survival Analysis | 6 | 2019 | 10073 | 0.160 |
Why?
|
Naphthalenes | 1 | 2019 | 198 | 0.160 |
Why?
|
Decision Making | 3 | 2020 | 3918 | 0.160 |
Why?
|
Withholding Treatment | 1 | 2023 | 616 | 0.160 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 883 | 0.150 |
Why?
|
Survival Rate | 6 | 2019 | 12719 | 0.150 |
Why?
|
Vitis | 2 | 2019 | 19 | 0.150 |
Why?
|
Patient Advocacy | 1 | 2020 | 360 | 0.150 |
Why?
|
Prospective Studies | 11 | 2023 | 54360 | 0.150 |
Why?
|
Central Nervous System Neoplasms | 2 | 2022 | 915 | 0.150 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2013 | 1520 | 0.150 |
Why?
|
Patient Selection | 4 | 2021 | 4237 | 0.140 |
Why?
|
Zimbabwe | 3 | 2021 | 135 | 0.140 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2021 | 549 | 0.140 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 1222 | 0.140 |
Why?
|
Treatment Failure | 3 | 2015 | 2635 | 0.140 |
Why?
|
Lung | 1 | 2015 | 9998 | 0.140 |
Why?
|
Ideal Body Weight | 1 | 2016 | 27 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2000 | 620 | 0.130 |
Why?
|
Radiopharmaceuticals | 3 | 2020 | 2650 | 0.130 |
Why?
|
Polymorphism, Restriction Fragment Length | 3 | 2013 | 767 | 0.130 |
Why?
|
Acetic Acid | 1 | 2015 | 60 | 0.130 |
Why?
|
Obesity | 2 | 2023 | 12933 | 0.120 |
Why?
|
Neoplasm Invasiveness | 5 | 2019 | 3593 | 0.120 |
Why?
|
Appointments and Schedules | 1 | 2019 | 442 | 0.120 |
Why?
|
Patient Care | 1 | 2021 | 621 | 0.120 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 928 | 0.120 |
Why?
|
Inhalation | 1 | 2015 | 143 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2020 | 905 | 0.120 |
Why?
|
Extremities | 1 | 2020 | 867 | 0.120 |
Why?
|
Carbohydrate Metabolism | 1 | 2015 | 262 | 0.110 |
Why?
|
Color | 1 | 2015 | 299 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 6 | 2020 | 20556 | 0.110 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 258 | 0.110 |
Why?
|
Polymerase Chain Reaction | 3 | 2013 | 6074 | 0.110 |
Why?
|
Regression Analysis | 2 | 2014 | 6338 | 0.110 |
Why?
|
Volatilization | 1 | 2013 | 77 | 0.110 |
Why?
|
Crosses, Genetic | 2 | 2013 | 750 | 0.110 |
Why?
|
Pyrazoles | 1 | 2024 | 2008 | 0.110 |
Why?
|
Organs at Risk | 1 | 2015 | 359 | 0.110 |
Why?
|
Recombination, Genetic | 2 | 2012 | 1519 | 0.110 |
Why?
|
Chromosomes, Fungal | 1 | 2013 | 111 | 0.110 |
Why?
|
Peptide Elongation Factor G | 1 | 2012 | 12 | 0.100 |
Why?
|
Thinness | 1 | 2016 | 480 | 0.100 |
Why?
|
Benzimidazoles | 1 | 2018 | 858 | 0.100 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1852 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 943 | 0.100 |
Why?
|
Peptide Elongation Factors | 1 | 2012 | 62 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1156 | 0.100 |
Why?
|
DNA, Ribosomal | 1 | 2013 | 299 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 10199 | 0.100 |
Why?
|
Solvents | 1 | 2013 | 294 | 0.100 |
Why?
|
Patient Preference | 1 | 2019 | 925 | 0.100 |
Why?
|
Risk Factors | 12 | 2024 | 74115 | 0.100 |
Why?
|
Tumor Burden | 2 | 2015 | 1892 | 0.100 |
Why?
|
Flavoring Agents | 1 | 2012 | 53 | 0.100 |
Why?
|
Cell Respiration | 1 | 2012 | 201 | 0.100 |
Why?
|
Ultrasonography, Mammary | 1 | 2013 | 239 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 3027 | 0.100 |
Why?
|
Quality of Life | 4 | 2024 | 13347 | 0.090 |
Why?
|
Hydrogen Sulfide | 1 | 2012 | 141 | 0.090 |
Why?
|
Estrogen Receptor alpha | 1 | 2015 | 583 | 0.090 |
Why?
|
Radiation Dosage | 4 | 2011 | 1956 | 0.090 |
Why?
|
Food Industry | 1 | 2011 | 66 | 0.090 |
Why?
|
Patient Compliance | 1 | 2021 | 2688 | 0.090 |
Why?
|
Fluorescence | 1 | 2013 | 756 | 0.090 |
Why?
|
Heptanoic Acids | 1 | 2012 | 344 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 645 | 0.090 |
Why?
|
Body Burden | 1 | 2010 | 158 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2015 | 6474 | 0.080 |
Why?
|
Scattering, Radiation | 1 | 2011 | 490 | 0.080 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2013 | 1540 | 0.080 |
Why?
|
Deoxycytidine | 1 | 2014 | 878 | 0.080 |
Why?
|
Surgical Instruments | 1 | 2011 | 383 | 0.080 |
Why?
|
Beverages | 2 | 2013 | 821 | 0.080 |
Why?
|
Medical Oncology | 1 | 2021 | 2317 | 0.080 |
Why?
|
Mastectomy, Extended Radical | 1 | 2008 | 3 | 0.080 |
Why?
|
Palliative Care | 3 | 2021 | 3592 | 0.080 |
Why?
|
Young Adult | 7 | 2024 | 59179 | 0.080 |
Why?
|
Prognosis | 11 | 2022 | 29600 | 0.080 |
Why?
|
Species Specificity | 1 | 2013 | 2411 | 0.080 |
Why?
|
Temperature | 1 | 2015 | 2223 | 0.080 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4845 | 0.080 |
Why?
|
Radionuclide Imaging | 2 | 2008 | 1972 | 0.070 |
Why?
|
Metabolic Networks and Pathways | 1 | 2012 | 789 | 0.070 |
Why?
|
Analgesics | 1 | 2014 | 1066 | 0.070 |
Why?
|
Postmenopause | 1 | 2016 | 2511 | 0.070 |
Why?
|
Prostatic Neoplasms | 2 | 2021 | 11106 | 0.070 |
Why?
|
Breast Implants | 2 | 2024 | 407 | 0.070 |
Why?
|
Pandemics | 3 | 2023 | 8645 | 0.070 |
Why?
|
Phenotype | 3 | 2015 | 16571 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1371 | 0.070 |
Why?
|
Radiographic Image Enhancement | 1 | 2011 | 876 | 0.070 |
Why?
|
Radiation Protection | 1 | 2010 | 424 | 0.070 |
Why?
|
Saccharomycetales | 1 | 2007 | 72 | 0.070 |
Why?
|
Discriminant Analysis | 1 | 2006 | 223 | 0.070 |
Why?
|
Confidence Intervals | 1 | 2012 | 2925 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2012 | 8998 | 0.070 |
Why?
|
Nomograms | 1 | 2008 | 230 | 0.070 |
Why?
|
Pyrroles | 1 | 2012 | 1125 | 0.060 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13635 | 0.060 |
Why?
|
Carboplatin | 2 | 2022 | 793 | 0.060 |
Why?
|
Genetic Engineering | 1 | 2011 | 931 | 0.060 |
Why?
|
Overweight | 1 | 2016 | 2417 | 0.060 |
Why?
|
Activities of Daily Living | 1 | 2014 | 2417 | 0.060 |
Why?
|
Radiometry | 1 | 2010 | 812 | 0.060 |
Why?
|
Saccharomyces cerevisiae Proteins | 2 | 2012 | 1836 | 0.060 |
Why?
|
Analysis of Variance | 4 | 2011 | 6224 | 0.060 |
Why?
|
Mammary Arteries | 1 | 2004 | 81 | 0.060 |
Why?
|
Thoracic Vertebrae | 1 | 2008 | 597 | 0.060 |
Why?
|
Practice Guidelines as Topic | 4 | 2016 | 7389 | 0.050 |
Why?
|
Mediastinum | 1 | 2004 | 266 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2012 | 3680 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2013 | 5863 | 0.050 |
Why?
|
Patient Care Team | 1 | 2013 | 2515 | 0.050 |
Why?
|
Age Factors | 6 | 2021 | 18381 | 0.050 |
Why?
|
Genotype | 2 | 2015 | 12978 | 0.050 |
Why?
|
Spinal Neoplasms | 1 | 2008 | 703 | 0.050 |
Why?
|
Decision Support Techniques | 2 | 2013 | 1998 | 0.050 |
Why?
|
Fast Neutrons | 1 | 2001 | 18 | 0.050 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2001 | 36 | 0.050 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2006 | 739 | 0.050 |
Why?
|
Vesicular Transport Proteins | 1 | 2003 | 376 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2007 | 1722 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2021 | 12447 | 0.040 |
Why?
|
Risk Assessment | 3 | 2021 | 23972 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 36402 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2015 | 9417 | 0.040 |
Why?
|
Health Services Misuse | 1 | 2021 | 244 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2011 | 3567 | 0.040 |
Why?
|
Incidence | 3 | 2024 | 21337 | 0.040 |
Why?
|
Mitochondria | 1 | 2012 | 3619 | 0.040 |
Why?
|
Cicatrix | 1 | 2005 | 785 | 0.040 |
Why?
|
Time Factors | 5 | 2017 | 39913 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 156 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2021 | 421 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2506 | 0.040 |
Why?
|
Administration, Oral | 2 | 2018 | 4010 | 0.040 |
Why?
|
Software | 1 | 2012 | 4431 | 0.040 |
Why?
|
Membrane Transport Proteins | 1 | 2003 | 1034 | 0.040 |
Why?
|
Disease Progression | 1 | 2015 | 13495 | 0.040 |
Why?
|
Perineum | 1 | 1999 | 208 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12043 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 551 | 0.040 |
Why?
|
Breast Implantation | 1 | 2019 | 219 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 708 | 0.030 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12966 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2137 | 0.030 |
Why?
|
Central Nervous System | 1 | 2022 | 1333 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4910 | 0.030 |
Why?
|
Anthracyclines | 1 | 2017 | 285 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2214 | 0.030 |
Why?
|
Immunoconjugates | 1 | 2022 | 951 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2024 | 2864 | 0.030 |
Why?
|
Reoperation | 2 | 2017 | 4300 | 0.030 |
Why?
|
Heterozygote | 1 | 2021 | 2780 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2005 | 5239 | 0.030 |
Why?
|
Fruit | 1 | 2019 | 1157 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3206 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6370 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 982 | 0.030 |
Why?
|
United States | 4 | 2023 | 72272 | 0.030 |
Why?
|
DNA, Fungal | 2 | 2007 | 275 | 0.030 |
Why?
|
Hormones | 1 | 2017 | 869 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2014 | 26049 | 0.030 |
Why?
|
Odds Ratio | 2 | 2017 | 9643 | 0.030 |
Why?
|
Glucose | 2 | 2003 | 4345 | 0.030 |
Why?
|
Soft Tissue Neoplasms | 1 | 2001 | 1158 | 0.030 |
Why?
|
Neoplasms | 1 | 2001 | 22131 | 0.020 |
Why?
|
Postoperative Period | 1 | 2016 | 1813 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2021 | 2570 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1386 | 0.020 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 410 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2008 | 6340 | 0.020 |
Why?
|
Cohort Studies | 4 | 2017 | 41457 | 0.020 |
Why?
|
Air | 1 | 2011 | 187 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7995 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2003 | 4935 | 0.020 |
Why?
|
Male | 5 | 2021 | 360358 | 0.020 |
Why?
|
Animals | 2 | 2018 | 168201 | 0.020 |
Why?
|
Sarcoma | 1 | 2001 | 1800 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2018 | 2326 | 0.020 |
Why?
|
Technology, Radiologic | 1 | 2009 | 160 | 0.020 |
Why?
|
Automation | 1 | 2011 | 585 | 0.020 |
Why?
|
Neutropenia | 1 | 2014 | 885 | 0.020 |
Why?
|
Ribosomes | 1 | 2012 | 500 | 0.020 |
Why?
|
Remission Induction | 1 | 2014 | 2391 | 0.020 |
Why?
|
Mutagenesis | 1 | 2012 | 1230 | 0.020 |
Why?
|
Xanthenes | 1 | 2007 | 71 | 0.020 |
Why?
|
Estrogen Antagonists | 1 | 2008 | 150 | 0.020 |
Why?
|
RNA, Ribosomal, 5.8S | 1 | 2007 | 2 | 0.020 |
Why?
|
Gestational Age | 1 | 2016 | 3577 | 0.020 |
Why?
|
Fatigue | 1 | 2014 | 1550 | 0.020 |
Why?
|
Radiology | 1 | 2021 | 2113 | 0.020 |
Why?
|
Consensus | 1 | 2016 | 3117 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3451 | 0.020 |
Why?
|
Cell Death | 1 | 2012 | 1677 | 0.020 |
Why?
|
DNA Fingerprinting | 1 | 2007 | 114 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2003 | 7847 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4642 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 14018 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2014 | 1182 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2006 | 368 | 0.020 |
Why?
|
Sequence Analysis, Protein | 1 | 2007 | 261 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2006 | 504 | 0.020 |
Why?
|
Radiation Pneumonitis | 1 | 2005 | 102 | 0.020 |
Why?
|
Preoperative Care | 1 | 2014 | 2241 | 0.010 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2008 | 592 | 0.010 |
Why?
|
Markov Chains | 1 | 2007 | 965 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15251 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5430 | 0.010 |
Why?
|
Australia | 1 | 2007 | 1248 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2012 | 3419 | 0.010 |
Why?
|
Genetic Complementation Test | 1 | 2003 | 555 | 0.010 |
Why?
|
Therapy, Computer-Assisted | 1 | 2005 | 266 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 22148 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2008 | 15498 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10754 | 0.010 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2006 | 517 | 0.010 |
Why?
|
Perception | 1 | 2008 | 1198 | 0.010 |
Why?
|
Beer | 1 | 2002 | 134 | 0.010 |
Why?
|
Malus | 1 | 2002 | 49 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2011 | 20074 | 0.010 |
Why?
|
Polyploidy | 1 | 2002 | 119 | 0.010 |
Why?
|
Observer Variation | 1 | 2007 | 2606 | 0.010 |
Why?
|
ROC Curve | 1 | 2008 | 3575 | 0.010 |
Why?
|
Protein Subunits | 1 | 2003 | 942 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2007 | 2700 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3607 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2003 | 2747 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6233 | 0.010 |
Why?
|
Phylogeny | 1 | 2007 | 2806 | 0.010 |
Why?
|
Cell Line | 1 | 2012 | 15576 | 0.010 |
Why?
|
Cartilage | 1 | 2001 | 806 | 0.010 |
Why?
|
Biopsy | 1 | 2008 | 6762 | 0.010 |
Why?
|
DNA, Mitochondrial | 1 | 2002 | 865 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4457 | 0.010 |
Why?
|
Meningeal Neoplasms | 1 | 2004 | 1245 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9313 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 29868 | 0.010 |
Why?
|
Ultrasonography | 1 | 2007 | 5964 | 0.010 |
Why?
|
Hypertension | 1 | 2014 | 8529 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2008 | 3879 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 11874 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2016 | 15612 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13382 | 0.010 |
Why?
|
Logistic Models | 1 | 2008 | 13245 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 15908 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2003 | 13441 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2008 | 14591 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 9461 | 0.010 |
Why?
|
Genetic Variation | 1 | 2007 | 6561 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14648 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2002 | 4739 | 0.010 |
Why?
|
Physicians | 1 | 2008 | 4583 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 88234 | 0.000 |
Why?
|
Transcription Factors | 1 | 2003 | 12116 | 0.000 |
Why?
|
Mutation | 1 | 2003 | 30016 | 0.000 |
Why?
|